Overview

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Status:
WITHDRAWN
Trial end date:
2025-03-18
Target enrollment:
Participant gender:
Summary
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with Primary Sclerosing Cholangitis.
Phase:
PHASE2
Details
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Treatments:
aldafermin